Afobazole
| File:Afobazole structure.png | |
| Systematic (IUPAC) name | |
|---|---|
|
5-ethoxy-2-[2-(morpholino)-ethylthio]benzimidazole | |
| Clinical data | |
| Routes of administration | Oral |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | 173352-39-1 |
| ATC code | none |
| PubChem | CID 9862937 |
| Chemical data | |
| Formula | C15H21N3O2S |
| Molar mass | 307.410 g/mol[[Script error: No such module "String".]] |
| Script error: No such module "collapsible list". | |
Afobazole is an anxiolytic drug launched in Russia in the early 2000s. It produces anxiolytic and neuroprotective effects without any sedative or muscle relaxant actions, making it more selective in action than many currently used drugs for this application. Its mechanism of action remains poorly defined however, with GABAergic, NGF and BDNF release promoting, MT1 receptor antagonism, MT3 receptor antagonism, and sigma agonism all thought to have some involvement.[1][2][3][4][5] Clinical trials have shown afobazole to be well tolerated and reasonably effective for the treatment of anxiety, although it has yet to be introduced into widespread clinical use outside of Russia.[6]
References
Cite error: Invalid <references> tag;
parameter "group" is allowed only.
<references />, or <references group="..." />
| 35px | This drug article relating to the nervous system is a stub. You can help ssf by expanding it. |
 |
This medical article is a stub. You can help ssf by expanding it. |
- ↑ Neznamov GG, Siuniakov SA, Chumakov DV, Bochkarev VK, Seredenin SB. Clinical study of the selective anxiolytic agent afobazol. Eksp Klin Farmakol. 2001 Mar-Apr;64(2):15-9. Russian. PMID 11548440
- ↑ Silkina IV, Gan'shina TC, Seredin SB, Mirzoian RS. Gabaergic mechanism of cerebrovascular and neuroprotective effects of afobazole and picamilon. Eksp Klin Farmakol. 2005 Jan-Feb;68(1):20-4. Russian. PMID 15786959
- ↑ Seredin SB, Melkumian DS, Val'dman EA, Iarkova MA, Seredina TC, Voronin MV, Lapitskaia AS. Effects of afobazole on the BDNF content in brain structures of inbred mice with different phenotypes of emotional stress reaction. Eksp Klin Farmakol. 2006 May-Jun;69(3):3-6. Russian. PMID 16878488
- ↑ Antipova TA, Sapozhnikova DS, Bakhtina LIu, Seredenin SB. Selective anxiolytic afobazole increases the content of BDNF and NGF in cultured hippocampal HT-22 line neurons. Eksp Klin Farmakol. 2009 Jan-Feb;72(1):12-4. Russian. PMID 19334503
- ↑ Seredenin SB, Antipova TA, Voronin MV, Kurchashova SY, Kuimov AN. Interaction of Afobazole with sigma(1)-Receptors. Bull Exp Biol Med. 2009 Jul;148(1):42-4. English, Russian. PMID 19902093
- ↑ Medvedev VE, Trosnova AP, Dobrovol'skiĭ AV. Psychopharmacotherapy of anxiety disorders in patients with cardio-vascular diseases: the use of aphobazole. Zh Nevrol Psikhiatr Im S S Korsakova. 2007;107(7):25-9. Russian. PMID 18379478
- Pages with script errors
- Pages with broken file links
- Drugs with non-standard legal status
- Infobox drug tracked parameters
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs not assigned an ATC code
- Articles containing unverified chemical infoboxes
- 2Fix
- Anxiolytics
- Morpholines
- Thioethers
- Benzimidazoles
- Phenol ethers
- Nervous system drug stubs
- Medicine stubs
